Research map: Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis

Back to the article

Papers in this map

  1. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele · Peter Gordon Middleton · 2019 · 2219 citations · Cited by this paper
  2. TAP1 Deficiency Mimicking Primary Ciliary Dyskinesia in a Child With Recurrent Sinopulmonary Infections: A Case Report · 2026 · Related
  3. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial · Harry G.M. Heijerman · 2019 · 1424 citations · Cited by this paper
  4. Volumetric Capnography for Assessing Pre‐ and Post‐Operative Intrapulmonary Shunt in Congenital Pulmonary Lymphangiectasia: A Case Report · 2026 · Related
  5. VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles · D. Keating · 2018 · 747 citations · Cited by this paper
  6. Comment on “Early Life Food Desert Status Is Associated With Alpha and Gamma Tocopherol Levels and Infant Lung Function” · 2026 · Related
  7. Cystic fibrosis in the year 2020: A disease with a new face · K. De Boeck · 2020 · 335 citations · Cited by this paper
  8. Agreement of Diaphragmatic Excursion Between Anterior Subcostal and Posterior Subcostal Ultrasonography in Premature Neonates · 2026 · Related
  9. Cystic Fibrosis · Thida Ong · 2023 · 318 citations · Cited by this paper
  10. Cystic Fibrosis Newborn Screening: Cost Trajectory as a Marker to Improve Health Outcomes · 2026 · Related
  11. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele · Edith T. Zemanick · 2021 · 310 citations · Cited by this paper
  12. Bronchodilator Responsiveness in Preterm‐Born Children With Chronic Lung Disease: Importance of Individualized Testing · 2026 · Related
  13. Cystic fibrosis: current therapeutic targets and future approaches · Misbahuddin M. Rafeeq · 2017 · 251 citations · Cited by this paper
  14. Performance Evaluation of a Novel Cystic Fibrosis Caregiver Burden Measure Demonstrates Significant Challenges for Parents of Children With CF During the Early Years: The Irish Comparative Outcomes Study (ICOS) · 2026 · Related
  15. Microbiology of Cystic Fibrosis Airway Disease · Ana C. Blanchard · 2019 · 170 citations · Cited by this paper
  16. Administrative Prevalence and Healthcare Utilization of Pediatric Cystic Fibrosis in a Middle‐Income Country: A 10‐Year Analysis of National Administrative Data · 2026 · Related
  17. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele · Jennifer L. Goralski · 2023 · 143 citations · Cited by this paper
  18. Respiratory Outcomes in Children With Neonatal Respiratory Distress Syndrome and Monoallelic ABCA3 Variants · 2026 · Related
  19. Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials · Ahmet Uluer · 2023 · 74 citations · Cited by this paper
  20. The Rapid Reduction of Infection-Related Visits and Antibiotic Use Among People With Cystic Fibrosis After Starting Elexacaftor-Tezacaftor-Ivacaftor · Aaron C. Miller · 2022 · 51 citations · Cited by this paper
  21. Impact of Elexacaftor–Tezacaftor–Ivacaftor on lung disease in cystic fibrosis · Courtney A. Gushue · 2023 · 36 citations · Cited by this paper
  22. Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutations · Galit Livnat · 2022 · 20 citations · Cited by this paper
  23. Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: A retrospective review · Emma L. Guenther · 2023 · 18 citations · Cited by this paper
  24. The Effect of Elexacaftor/Tezacaftor/Ivacaftor on Hospitalizations and Intravenous Antibiotic Use · Eric Walter · 2022 · 15 citations · Cited by this paper
  25. Early and sustained improvements of lung clearance index from two to sixteen weeks of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis—a real world study · Dorothea Appelt · 2023 · 11 citations · Cited by this paper
  26. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis · Cindy L. Williams · 2025 · 6 citations · Cited by this paper
  27. De-escalation of Medications After Initiation of Elexacaftor-Tezacaftor-Ivacaftor in Children 6 to 11 Years of Age With Cystic Fibrosis · Eva M. Byerley · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)